BioCardia, Inc. (NASDAQ:BCDA) CEO Purchases $50,129.86 in Stock

BioCardia, Inc. (NASDAQ:BCDA) CEO Peter Altman bought 26,246 shares of the company’s stock in a transaction on Wednesday, April 23rd. The stock was purchased at an average cost of $1.91 per share, for a total transaction of $50,129.86. Following the completion of the transaction, the chief executive officer now directly owns 138,966 shares of the company’s stock, valued at approximately $265,425.06. The trade was a 23.28 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Peter Altman also recently made the following trade(s):

• On Tuesday, April 15th, Peter Altman acquired 100 shares of BioCardia stock. The shares were bought at an average cost of $2.14 per share, for a total transaction of $214.00.
• On Thursday, April 10th, Peter Altman bought 300 shares of BioCardia stock. The shares were acquired at an average cost of $1.99 per share, for a total transaction of $597.00.
• On Monday, April 7th, Peter Altman bought 500 shares of BioCardia stock. The stock was acquired at an average cost of $1.96 per share, with a total value of $980.00.
• On Thursday, April 3rd, Peter Altman acquired 1,200 shares of BioCardia stock. The stock was acquired at an average cost of $2.24 per share, with a total value of $2,688.00.
• On Monday, March 3rd, Peter Altman purchased 500 shares of BioCardia stock. The shares were purchased at an average cost of $2.11 per share, with a total value of $1,055.00.
• On Friday, February 7th, Peter Altman acquired 600 shares of BioCardia stock. The stock was bought at an average cost of $2.48 per share, with a total value of $1,488.00.
• On Wednesday, January 29th, Peter Altman acquired 500 shares of BioCardia stock. The stock was bought at an average cost of $2.40 per share, with a total value of $1,200.00.

BioCardia Stock Performance

NASDAQ:BCDA opened at $1.97 on Monday. The firm’s fifty day moving average is $2.27 and its two-hundred day moving average is $2.30. The firm has a market cap of $9.22 million, a price-to-earnings ratio of -0.47 and a beta of 1.21. BioCardia, Inc. has a one year low of $1.63 and a one year high of $6.15.

BioCardia (NASDAQ:BCDA) last posted its earnings results on Wednesday, March 26th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.62. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. During the same quarter last year, the business earned ($8.19) earnings per share. As a group, equities research analysts predict that BioCardia, Inc. will post -3.52 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Alliance Global Partners upgraded shares of BioCardia from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 30th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BioCardia stock. CM Management LLC purchased a new stake in shares of BioCardia, Inc. (NASDAQ:BCDA) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 25,000 shares of the company’s stock, valued at approximately $54,000. CM Management LLC owned 0.55% of BioCardia as of its most recent filing with the SEC. Institutional investors and hedge funds own 20.57% of the company’s stock.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.